Market Intelligence
Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.
In the latest episode of the In Vivo podcast, Citeline’s expert panel of reporters and analysts unpack the biggest deals, trends and innovations following the J.P. Morgan Healthcare Conference.
Improving reimbursement and integrating digital process across health care should be two priorities for the incoming German coalition, says Martin Walger, chief executive of the IVD industry association, the VDGH, in part two of his interview with In Vivo.
Beyond the cost savings of biosimilars, the true evolution in wet AMD treatment is happening by companies developing next-generation therapies that aim to reduce injection burden, introduce novel mechanisms, and potentially alter disease progression.
Ten $1bn+ alliances were penned in January, and two exceeded $2bn.
During Q4, biopharmas brought in an aggregate $16.8bn in financing and device company fundraising totaled $2.3bn; while in vitro diagnostic firms and research tools players raised $294m.
Lawmaking in Germany came to a halt after the federal election was called, meaning cardiovascular detection and pharmacy legislation were put on hold. In part one of a two-part interview on key themes for industry, Martin Walger, chief executive of the IVDs industry association, the VDGH, lays out the hopes and fears of IVD companies in the run up to the late February vote.
While Japan looks set to further improve policies to support ventures and ease market entry this year, these will contrast with ongoing reimbursement price controls.
In September last year, J&J lost a court case surrounding its 2019 purchase of Auris health, and was ordered to pay over $1bn in damages. Reactions to the potentially precedent-setting news were harsh and quick. In Vivo spoke to legal, M&A and BD experts from across the medtech industry to learn more about the true impacts.
In Vivo caught up with Najat Khan, chief R&D and commercial officer at Recursion since mid-2024, about her new roles, the special combination with Exscientia and the company's clinical pipeline.
Now that one of the most controversial pharma M&As of 2024 has closed, did overtures to concerned customers and extended prenotification discussions help Novo and Catalent seal the deal?
Boston-area biotech Apnimed expects Phase III readouts for its obstructive sleep apnea combination drug by May. Patients with OSA are desperate for a pill to treat the condition, and GLP-1 agonists are only part of the solution.
The J.P. Morgan Healthcare Conference and Biotech Showcase revealed what investors are really thinking about the health of the capital markets this year.
Manu Chakravarthy, Roche’s head of the resurrected cardiometabolic division, lays out his four-pillared strategy to place the company in direct competition with Eli Lilly and Novo Nordisk.
The last quarter of 2024 was flush with venture financings for biotechs finding novel ways to incorporate AI into their processes.
Just a handful of big pharma approvals of 2024 are tipped to be multi-billion dollar blockbusters. Even though it is still early days for these drugs, the pull of M&A is looking increasingly strong for big pharma as more smaller firms go it alone.
As efforts to improve diversity in clinical trials gain momentum globally, regulators in the UK, the EU, Canada, Australia and Japan were asked about their efforts to support representative enrolment.
The year’s new drugs included the first drug approved for non-alcoholic steatohepatitis (NASH) and two drugs for primary biliary cholangitis (PBC).
As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.
France’s medtech sector is strong, growing and innovative. In Vivo spoke to several French medtech leaders about the unique features and pitfalls their industry may face.